LONDON, April 23, 2014 /PRNewswire/ --
The trading session on Tuesday, April 22, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,514.37, up 0.40% and the NASDAQ Composite closed at 4,161.46, up 0.97%. The S&P 500 finished the session 0.41% higher at 1,879.55. The gains were broad based as eight out of ten sectors finished on a positive note. A number of stocks saw large movements, including Arrowhead Research Corp. (NASDAQ: ARWR), Endocyte Inc. (NASDAQ: ECYT), Ambac Financial Group Inc. (NASDAQ: AMBC) and ZIOPHARM Oncology Inc. (NASDAQ: ZIOP). Free technical research on ARWR, ECYT, AMBC and ZIOP can be downloaded upon signing up at:
On Tuesday, shares in Arrowhead Research Corp. ended the session at $13.52, up 2.89%. A total of 2.09 million shares were traded as compared with its three months average volume of 2.04 million shares. During the session, the stock traded between $13.02 and $14.39. Arrowhead Research Corp.'s shares have advanced 9.12% in the previous three trading sessions and 24.61% since the beginning of this year, while the same has declined 34.69% in the last one month. The S&P 500 Health Care Sector Index mapped a gained of 1.04% during the trading session, and the same has charted up 1.35% in the previous three months. Further, the company's stock has a Relative Strength Index (RSI) of 36.59 and is trading above its 200-day moving average. Arrowhead Research Corp.'s 50-day moving average of $19.36 is above its 200-day moving average of $10.17. Sign up today to read free research on ARWR at:
Endocyte Inc.'s stock closed the day at $19.93, which is 9.63% higher than its previous day's closing price of $18.18. On Tuesday, the stock oscillated between $18.29 and $20.44 during the trading session with a trading volume of 1.86 million shares, which was above its three months average volume of 1.27 million shares. Shares of Endocyte Inc. have gained 6.86% in the previous three trading sessions and 86.61% since the beginning of this year, while the stock has lost 29.25% in the last one month. The S&P 500 Health Care Sector Index advanced 1.04% during the trading session and 2.25% in the previous three trading sessions. Moreover, the company's stock has an RSI of 44.69 and is trading above its 50-day and 200-day moving averages of $17.49 and $14.26, respectively. Sign up today to read free research on ECYT at:
Shares in Ambac Financial Group Inc. finished the trading session at $31.97, up 12.21%. A total of 1.81 million shares were traded, which was above its three months average volume of 0.85 million shares. The stock vacillated between $30.05 and $32.20 during the trading session. The company's stock traded at a PE ratio of 4.56. Ambac Financial Group Inc.'s shares have advanced 11.16% in the previous three trading sessions and 30.17% on YTD basis, while the same has edged lower by 1.60% in the last one month. The S&P 500 Financials Sector Index declined 1.96% in the previous one month, while the NASDAQ Composite Index fell by 2.70% during the same period. Additionally, the company's stock has an RSI of 40.05 and is trading above its 50-day and 200-day moving averages of $30.02 and $24.12, respectively. Sign up today to read free research on AMBC at:
On Tuesday, ZIOPHARM Oncology Inc.'s stock surged 8.26%, finishing the day at $3.80. The stock fluctuated between $3.54 and $3.86 during the trading session with a trading volume of 1.64 million shares as compared with its three months average volume of 1.09 million shares. Shares of ZIOPHARM Oncology Inc. have surged 12.43% over the previous three trading sessions, while the same has lost 26.50% in the last one month and 12.44% since the start of this year. The S&P 500 Health Care Sector Index gained 1.04% during the trading session, and the same has advanced 4.84% on YTD basis. Furthermore, the company's stock has an RSI of 35.49 and is trading below its 50-day and 200-day moving averages of $4.34 and $3.83, respectively. Sign up today to read free research on ZIOP at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.